Abstract
Selexipag (Uptravi®) is a highly selective, long-acting, nonprostanoid, prostacyclin receptor agonist that is being developed by Actelion Pharmaceuticals Ltd and Nippon Shinyaku. Oral selexipag is approved in the USA for the treatment of pulmonary arterial hypertension (PAH; WHO Group I) to delay disease progression and reduce the risk of hospitalization for PAH. It has subsequently been approved in Canada for the long-term treatment of PAH, and received a positive opinion in the EU for the treatment of PAH in adult patients with WHO functional class II–III. Selexipag received orphan drug designation for the treatment of PAH in Japan in 2014 and is in undergoing regulatory review in several countries for use in this indication. In the large, event-driven, phase III GRIPHON trial, selexipag reduced the risk of the primary composite endpoint of death or a complication related to PAH (whichever occurred first) by 40 % compared with placebo in patients with PAH (80 % were also receiving stable dosages of an endothelin receptor antagonist and/or a phosphodiesterase 5 inhibitor). This article summarizes the milestones in the development of selexipag leading to this first approval for PAH.
Similar content being viewed by others
References
Delcroix M, Howard L. Pulmonary arterial hypertension: the burden of disease and impact on quality of life. Eur Respir Rev. 2015;24:621–9.
Mandras SA, Gilkin RJ, Pruett JA, et al. Pulmonary arterial hypertension: progress and challenges in the modern treatment era. Am J Manag Care. 2014;20(9):S191–9.
Asaki T, Kuwano K, Morrison K, et al. Selexipag: an oral and selective IP prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension. J Med Chem. 2015;58(18):7128–37.
Actelion Pharmaceuticals US Inc. UPTRAVI® (selexipag) tablets, for oral use: US prescribing information. 2015. http://www.fda.gov/. Accessed 5 Jan 2016.
FirstWord Pharma. Actelion receives Health Canada approval for Uptravi (selexipag) for the long-term treatment of pulmonary arterial hypertension. 2016. http://www.firstwordpharma.com/node/1353734#axzz3yTk90Lnp. Accessed 28 Jan 2016.
European Medicines Agency. CHMP summary of positive opinion for Uptravi. 2016. http://www.ema.europa.eu/. Accessed 2 Feb 2016.
Nippon Shinyaku. Orphan drug designation of pulmonary arterial hypertension drug selexipag [media release]. 2014. http://www.nippon-shinyaku.co.jp. Accessed 23 Dec 2015.
Kuwano K, Hashino A, Noda K, et al. A long-acting and highly selective prostacyclin receptor agonist prodrug, 2-{4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}-N-(methylsulfonyl)acetamide (NS-304), ameliorates rat pulmonary hypertension with unique relaxant responses of its active form, {4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}acetic acid (MRE-269), on rat pulmonary artery. J Pharmacol Exp Ther. 2008;326(3):691–9.
Actelion Ltd, Nippon Shinyaku. Actelion and Nippon Shinyaku enter into a license agreement on novel PAH compound [media release]. 2008. http://www.actelion.com. Accessed 1 Jan 2016.
Kuwano K, Hashino A, Asaki T, et al. 2-[4-[(5,6-Diphenylpyrazin-2-yl)(isopropyl)amino]butoxy]-N-(methylsulfonyl)acetamide (NS-304), an orally available and long-acting prostacyclin receptor agonist prodrug. J Pharmacol Exp Ther. 2007;322(3):1181–8.
Morrison K, Ernst R, Hess P, et al. Selexipag: a selective prostacyclin receptor agonist that does not affect rat gastric function. J Pharmacol Exp Ther. 2010;335(1):249–55.
Gatfield J, Menyhart K, Nayler O. Anti-contractile and anti-proliferative responses in human pulmonary arterial smooth muscle cells induced by ACT-333679, the active metabolite of selexipag, a non-prostanoid selective prostacyclin receptor agonist [abstract no. P2353]. Eur Respir J. 2014;44(Suppl 58):P2353.
Gatfield J, Menyhart K, Morrison K, et al. The non-prostanoid prostacyclin receptor agonist ACT-333679, the active metabolite of selexipag, is characterized by low beta-arrestin recruitment and receptor internalization activity [abstract no. 1110–174]. J Am Coll Cardiol. 2015;65(10 Suppl):A1542.
Morrison K, Wanner D, Gatfield J, et al. Repeated oral administration of the selective prostacyclin receptor agonist selexipag does not cause tachyphylaxis in spontaneously hypertensive rats [abstract]. J Am Coll Cardiol. 2015;65(10 Suppl):A1558.
Simonneau G, Torbicki A, Hoeper MM, et al. Selexipag: an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension. Eur Respir J. 2012;40(4):874–80.
Hoch M, Darpo B, Remenova T, et al. A thorough QT study in the context of an uptitration regimen with selexipag, a selective oral prostacyclin receptor agonist. Drug Des Devel Ther. 2015;9:175–85.
Niglis S, Bruderer S, Okubo K, et al. Niglis S, Bruderer S, Okubo K, et al. Investigation of potential pharmacodynamic and pharmacokinetic interactions between selexipag and warfarin in healthy male subjects [abstract no. 1690802]. In: American College of Clinical Pharmacology Annual Meeting; 2013.
Bruderer S, Hurst N, Kaufmann P, et al. Multiple-dose up-titration study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of selexipag, an orally available selective prostacyclin receptor agonist, in healthy subjects. Pharmacology. 2014;94(3–4):148–56.
Kaufmann P, Okubo K, Bruderer S, et al. Pharmacokinetics and tolerability of the novel oral prostacyclin IP receptor agonist selexipag. Am J Cardiovasc Drugs. 2015;15(3):195–203.
Baldoni D, Bruderer S, Muhsen N. Bioequivalence of different dose-strength tablets of selexipag, a selective prostacyclin receptor agonist, in a multiple-dose up-titration study. Int J Clin Pharmacol Ther. 2015;53(9):788–98.
Fischer N, Kaufmann P, Bruderer S, et al. Pharmacokinetics of selexipag in subjects with mild, moderate, or severe hepatic impairment compared with healthy subjects [abstract no. PP194]. Clin Ther. 2013;35(8):e77–8.
Kaufmann P, Niglis S, Bruderer S, et al. Effect of lopinavir/ritonavir on the pharmacokinetics of selexipag an oral prostacyclin receptor agonist and its active metabolite in healthy subjects. Br J Clin Pharmacol. 2015;80(4):670–7.
Sitbon O, Channick R, Chin KM, et al. Selexipag for the treatment of pulmonary arterial hypertension. N Engl J Med. 2015;373(26):2522–33.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Disclosure
The preparation of this review was not supported by any external funding. During the peer review process the manufacturer of selexipag was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the author on the basis of scientific completeness and accuracy. Lesley Scott is a salaried employee of Adis, Springer SBM.
Additional information
This profile has been extracted and modified from the AdisInsight database. AdisInsight tracks drug development worldwide through the entire development process, from discovery, through pre-clinical and clinical studies to market launch and beyond.
Rights and permissions
About this article
Cite this article
Scott, L.J. Selexipag: First Global Approval. Drugs 76, 413–418 (2016). https://doi.org/10.1007/s40265-016-0549-4
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40265-016-0549-4